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our aim was to identify the risk factors associated with locoregional recurrence in resected distal bile 
duct cancer (DBDC), and to determine the subgroup that may benefit from adjuvant radiotherapy. 
Between 2001 and 2013, we retrospectively analyzed 93 patients with DBDC who had undergone 
curative resection. Patients who received adjuvant radiotherapy were excluded. The 3-year 
locoregional failure-free survival (LRFFS) and overall survival (OS) rates for all patients were 50.7%, 
and 53.2%, respectively. On multivariate analysis, the preoperative carcinoembryonic antigen (CEA) 
level, resection margin, histologic grade, T stage, and N stage were significant prognostic factors for 
LRFFS. Locoregional recurrence was observed in more than 78% of the patients who underwent R1 
resection and were node-positive, and the 3-year LRFFS rate was 19.3%. The 3-year LRFFS rate was 
46.9% in the patients who underwent R0 resection and were node-negative with more than 2 risk 
factors (preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage). On 
multivariate analysis for OS, patients with more than 2 risk factors showed a 7-fold higher risk of death, 
compared with patients with 1 or no risk factor. The important risk factors of locoregional failure in 
patients with DBDC who underwent resection were R1 resection and positive lymph nodes. Adjuvant 
radiotherapy should be considered for these patients to improve the oncologic outcomes. Patients 
undergoing selective R0 resection and those with node-negative status and multiple locoregional failure 
risk factors may benefit from adjuvant radiotherapy.
Curative resection is the treatment of choice for distal bile duct cancer (DBDC). However, the prognosis of DBDC 
remains unsatisfactory even after curative resection, with the 5-year overall survival (OS) rate at only approxi-
mately 25–48%1–7. One study showed that 52% of patients who underwent resection without adjuvant treatment 
had disease recurrence6. The prognosis after recurrence is dismal, with a median OS of only 6–9 months1–3.
Although the efficacy of adjuvant treatment after curative resection remains controversial, adjuvant treatment 
is commonly used to improve the poor prognosis of DBDC. Adjuvant radiotherapy has been recommended to 
improve locoregional control and has increased survival4–6,8–10.
A better understanding of locoregional recurrence after resection for DBDC is essential in implementing 
radiotherapy and improving surgical outcomes. However, because of the rarity of DBDC11,12, the risk factors for 
locoregional recurrence have not been well established and research on prognostic factors influencing locore-
gional failure-free survival (LRFFS) is limited. Therefore, the aim of this study was to focus on locoregional recur-
rence after curative resection of DBDC. We analyzed the risk factors associated with locoregional recurrence in 
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patients undergoing surgical resection for DBDC and investigated the subgroup of patients who may benefit the 
most from adjuvant radiotherapy.
Results
Patient characteristics. The characteristics of the 93 included patients are listed in Table 1. The median age 
was 67 years (range, 34–81 years). The median preoperative and postoperative carbohydrate antigen (CA) 19–9 
levels were 96.6 U/mL and 14.8 (range, 1.8–4529) U/mL, respectively and the median preoperative carcinoembry-
onic antigen (CEA) level was 2.5 (range, 0.3–32.1) ng/mL. The preoperative CA 19–9 level of 1 patient was higher 
than 20040 U/mL. Nineteen patients underwent segmental resection of bile duct; 74 underwent pylorus-preserv-
ing pancreatoduodenectomy. After surgical resection, R0 resection was achieved in 79 patients (84.9%), and R1 
resection in 14 patients (15.1%). Metastatic lymph nodes (LNs) were found in 39.8% of patients.
Survival analysis and patterns of failure. The median follow-up was 46 months (range, 8–155 months) 
for the surviving patients. Of the surviving patients, 13 (13/45, 26.7%) were followed up for 3 years or less. The 
median OS was 47 months. The 3-year OS and LRFFS rates were 53.2% and 50.7%, respectively.
During follow-up, 56 patients (60.2%) were diagnosed with recurrence, and locoregional recurrence was the 
dominant type of failure. Locoregional recurrences were the first event in 50 patients (53.8%), and distant relapse 
occurred in 40 patients (43.0%). Thirty-four patients (36.6%) had both locoregional relapse and distant metasta-
sis. The liver was the most common site for primary metastatic recurrence.
Risk factors related to locoregional failure-free survival and overall survival. Initial locoregional 
recurrence was more frequent in patients with preoperative CA 19–9 level > 37 U/mL, positive resection margin 
(RM), T3 stage, and positive LNs (Table 1). Initial locoregional recurrence occurred in 85.7% and 78.4% of the 
patients with positive RM and positive LNs, respectively. Initial locoregional recurrence occurred in 23 (79.3%) 
of 29 patients who had positive LNs and negative RM. The preoperative and postoperative CA 19–9 level, RM, 
lymphovascular invasion, T stage, and N stage were significant prognostic factors for LRFFS (p < 0.05) (Table 2). 
Multivariate analysis showed that preoperative CEA level, RM, histologic grade, T stage, and N stage were inde-
pendent prognostic factors for LRFFS (p < 0.05) (Table 3).
All patients were divided into 3 locoregional recurrence risk groups according to risk factors (Table 4). As 
locoregional recurrence occurred in more than 78% of the patients with positive RM and LNs, these patients 
were defined as the high-risk group for locoregional recurrence (group 1, n = 42). The patients, with negative 
RM and LNs, were divided into 2 groups according to the preoperative CEA level, histologic grade, and T stage 
considering the 5 independent prognostic factors for LRFFS on multivariate analysis. The patients, who had more 
than 2 risk factors considering preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 
stage, were defined as group 2 (n = 12), and those who had less than 1 risk factor were defined as group 3 (n = 39). 
The locoregional recurrence rates of groups 1, 2, and 3 were 81.0%, 50.0%, and 25.6%, respectively (Table 1). The 
3-year LRFFS for groups 1, 2, and 3 were 19.3%, 46.9%, and 84.2%, respectively (Fig. 1). LRFFS was significantly 
different among the three groups (p < 0.05) (Table 2). Moreover, there were significant differences in LRFFS 
between groups 1 and 2, groups 2 and 3, and groups 1 and 3 (p < 0.05).
The results of univariate analysis of OS are summarized in Table 2. Univariate analysis showed that preop-
erative and postoperative CA 19–9 levels, RM, lymphovascular invasion, T stage, N stage, and locoregional 
recurrence risk group were significantly associated with OS (p < 0.05). For multivariate analysis, the analysis 
was conducted by substituting locoregional recurrence risk group. On multivariate analysis, locoregional recur-
rence risk group, postoperative CA19-9 level, and lymphovascular invasion were significantly associated with OS 
(P < 0.05) (Table 3). The patients in groups 1 and 2 showed approximately 8-fold and 7-fold increased risks of 
death, respectively, as compared with group 3 (p < 0.05).
Discussion
The role of adjuvant radiotherapy has not been well established. The literature regarding the benefit of adjuvant 
radiotherapy for DBDC is inconsistent4–6,8,9,13. For the appropriate selection of radiotherapy, risk factors associ-
ated with locoregional failure are thought to be an integral part of DBDC management. Several studies reported 
that 47–66% of patients with DBDC still experienced disease recurrence after undergoing surgical resection, and 
the initial locoregional recurrence rate was 26–65%1–3,6,7,14,15. This study was conducted in patients with DBDC 
who underwent resection but did not receive adjuvant radiotherapy, and the initial locoregional recurrence rate 
was 53.8%. Accordingly, adjuvant radiotherapy should be administered for selected patients with DBDC who 
undergo resection and are at a higher risk of locoregional failure regardless of whether the dominant type of fail-
ure is a locoregional recurrence or distant metastasis.
In this study, RM and LNs were found to be high risk factors of locoregional recurrence. However, Kim et al. 
found that N stage and perineural invasion were significantly associated with locoregional control in patients with 
resected extrahepatic biliary tract cancer16, while Choi et al. reported that the LN status and RM status were not 
significant factors for locoregional recurrence, and that poorly differentiated histologic grade was an independent 
prognostic factor for locoregional recurrence1. The discrepancy in the risk factors among the studies can be partly 
explained by the fact that radiotherapy is usually performed in patients with positive RM. In other words, as adju-
vant radiotherapy for patients with positive RM might be effective in controlling microscopic residual tumors, the 
RM may not be a risk factor of locoregional recurrence. A recent meta-analysis demonstrated that adjuvant chemo-
therapy or chemoradiotherapy significantly improved the survival of patients with biliary tract cancer with positive 
LNs or positive RM9. Our previous study showed that adjuvant chemoradiotherapy improved the clinical out-
comes of patients with resected extrahepatic bile duct cancer, particularly patients who underwent R1 resection8. 
Kim et al. reported that adjuvant chemotherapy or chemoradiotherapy was associated with a significant OS 
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Variable
Number of patients (%)
Loco-regional recurrence
p-valueYes No
Age (years) 0.277
   ≤65 35 (40.9) 23 (60.5) 15 (39.5)
   >65 55 (59.1) 27 (49.1) 28 (50.9)
Sex 0.108
   Male 59 (63.4) 28 (47.5) 31 (52.5)
   Female 34 (36.6) 22 (64.7) 12 (35.3)
Preoperative CA 19–9 (U/mL) 0.011
   <37 25 (26.9) 8 (32.0) 17 (68.0)
   ≥37 68 (73.1) 42 (61.8) 26 (38.2)
Postoperative CA 19–9 (U/mL) 0.337
   <37 81 (87.1) 42 (51.9) 39 (48.1)
   ≥37 12 (12.9) 8 (66.7) 4 (33.3)
Preoperative CEA (ng/mL) 0.255
   <5 73 (78.5) 37 (50.7) 36 (49.3)
   ≥5 20 (21.5) 13 (65.0) 7 (35.0)
Surgical procedure 0.912
   PPPD 74 (79.6) 40 (54.1) 34 (45.9)
   Segmental resection of bile duct 19 (20.4) 10 (52.6) 9 (47.4)
Resection margin 0.009
   R0 79 (84.9) 38 (48.1) 41 (51.9)
   R1 14 (15.1) 12 (85.7) 2 (14.3)
Histologic grade 0.255
   WD/MD 73 (78.5) 37 (50.7) 36 (49.3)
   PD 20 (21.5) 13 (65.0) 7 (35.0)
Lymphovascular invasion 0.161
   No 67 (72.0) 33 (49.3) 34 (50.7)
   Yes 26 (28.0) 17 (65.4) 9 (34.6)
Perineural invasion 0.981
   No 28 (30.1) 15 (53.6) 13 (46.4)
   Yes 65 (69.9) 35 (53.8) 30 (46.2)
T stage (AJCC 7th edition) 0.011
   T1-2 41 (44.1) 16 (39.0) 25 (61.0)
   T3 52 (55.9) 34 (65.4) 18 (34.6)
N stage (AJCC 7th edition) <0.001
   N0 56 (60.2) 21 (37.5) 35 (62.5)
   N1 37 (39.8) 29 (78.4) 8 (21.6)
N stage (AJCC 8th edition) 0.001
   N0 56 (60.2) 21 (37.5) 35 (62.5)
   N1 29 (31.2) 23 (79.3) 6 (20.7)
   N2 8 (8.6) 6 (75.0) 2 (25.0)
Adjuvant chemotherapy 0.619
   No 45 (48.4) 23 (51.1) 22 (48.9)
   Yes 48 (51.6) 27 (56.3) 21 (43.8)
Locoregional recurrence risk group <0.001
   Group 1 42 (45.2) 34 (81.0) 8 (19.0)
   Group 2 12 (12.9) 6 (50.0) 6 (50.0)
   Group 3 42 (45.2) 10 (25.6) 29 (74.4)
Table 1. Patient characteristics of all patients and relationship between patient characteristics and loco-
regional recurrence. CA, carbohydrate antigen; CEA, carcinoembryonic antigen; PPPD, pylorus-preserving 
pancreaticoduodenectomy; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; 
AJCC, American Joint Committee on Cancer Group 1 was defined as patients with positive resection margin 
or positive lymph nodes. Group 2 was defined as patients with negative resection margin and negative lymph 
nodes who possessed 2 or more risk factors (preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic 
grade, and T3 stage). Group 3 was defined as patients with negative resection margin and negative lymph nodes 
with 1 or no risk factor (preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage).
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Prognostic factor
3-y Survival rate (%)
LRFFS p-value OS p-value
Age (years) 0.276 0.493
   ≤65 43.3 48.5
   >65 55.9 56.5
Sex 0.167 0.636
   Male 56.1 60.5
   Female 41.5 39.2
Preoperative CA 19–9 (U/mL) 0.019 0.014
   <37 70.2 78.6
   ≥37 43.6 44.6
Postoperative CA 19–9 (U/mL) 0.001 <0.001
   <37 54.4 58.6
   ≥37 27.8 16.7
Preoperative CEA (ng/mL) 0.087 0.056
   <5 54.2 57.2
   ≥5 37.9 39.4
Surgical procedure 0.853 0.811
   PPPD 50.5 53.5
   Segmental resection of bile duct 51.7 52.1
Resection margin <0.001 <0.001
   R0 56.5 60.2
   R1 15.9 14.3
Histologic grade 0.104 0.268
   WD/MD 54.1 55.8
   PD 38.2 44.4
Lymphovascular invasion 0.008 <0.001
   No 57.2 64.1
   Yes 33.3 25.2
Perineural invasion 0.954 0.808
   No 47.2 50.8
   Yes 52.2 54.2
T stage (AJCC 7th edition) 0.003 0.002
   T1-2 69.6 69.7
   T3 35.1 40.0
N stage (AJCC 7th edition) <0.001 <0.001
   N0 70.4 69.8
   N1 19.3 29.0
N stage (AJCC 8th edition) <0.001 <0.001
   N0 70.4 69.8
   N1 21.6 34.1
   N2 25.0 12.5
Adjuvant chemotherapy 0.404 0.164
   No 58.6 63.0
   Yes 43.1 44.4
Locoregional recurrence risk group <0.001 <0.001
   Group 1 19.3 28.0
   Group 2 46.9 45.7
   Group 3 84.2 83.5
Table 2. Univariate analysis of prognostic factors for locoregional failure-free survival and overall survival. CA, 
carbohydrate antigen; CEA, carcinoembryonic antigen; PPPD, pylorus-preserving pancreaticoduodenectomy; 
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; AJCC, American Joint 
Committee on Cancer; LRFFS, locoregional failure-free survival; OS, overall survival. Group 1 was defined 
as patients with positive resection margin or positive lymph nodes. Group 2 was defined as patients with 
negative resection margin and negative lymph nodes who possessed 2 or more risk factors (preoperative CEA 
level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage). Group 3 was defined as patients with 
negative resection margin and negative lymph nodes with 1 or no risk factor (preoperative CEA level ≥ 5 ng/mL, 
poorly differentiated histologic grade, and T3 stage).
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advantage in patients with LN-positive R0-resected DBDC6. Therefore, adjuvant radiotherapy should be consid-
ered for locoregional control of RM-positive or LN-positive DBDC.
The benefit of adjuvant radiotherapy remains unclear for patients with DBDC and negative LNs treated with 
R0 resection. In this study, the locoregional recurrences rate was 25.6% in patients with 1 or no risk factor among 
preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage. Therefore, we believe that 
adjuvant radiotherapy may not improve the clinical outcomes of these patients. However, locoregional recurrence 
occurred in 50.0% of the patients who underwent R0 resection and had negative LNs with more than 2 risk fac-
tors, and the 5-year LRFFS was 46.9%; thus, patients with more than 2 risk factors showed a 7-fold higher risk 
for death compared with those with 1 or no risk factors on multivariate analysis for OS. Adjuvant radiotherapy 
may be helpful to increase survival outcome for some of these patients. Nevertheless, further studies should be 
performed to determine whether adjuvant radiotherapy can actually improve clinical outcomes of these patients.
There are several limitations of this study. First, this was a nonrandomized and retrospective study, and unrec-
ognized bias could be present. As this study was conducted at a single center, and the patients treated with adju-
vant radiotherapy were excluded, selection bias may have affected the results. Further, 13 surviving patients were 
followed up for 3 years or less which may also have generated selection bias. Additionally, because the present 
study involved a limited number of patients, the results of this study must be confirmed in larger studies in the 
future. Finally, CA 19–9 and CEA levels could show a false positive or negative result. Therefore, caution is needed 
when evaluating the recurrence or prognosis of the patients17.
In conclusion, R1 resection and positive LNs were important prognostic factors for locoregional recurrence in 
patients with DBDC. Therefore, we recommend adjuvant radiotherapy with curative resection for patients with 
DBDC treated with R1 resection or those who have positive LNs. Adjuvant radiotherapy for patients treated with 
R0 resection and those with negative LNs who exhibit multiple locoregional risk factors may reduce locoregional 
failure, which translates into OS benefits. Future well-designed, randomized, controlled studies are necessary to 
clarify the role of adjuvant radiotherapy.
Methods
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as revised in 1983, 
and was approved by Institutional Review Board of Severance Hospital. The patient records/information was 
anonymized and de-identified prior to analysis, and informed consent was not obtained from each participant. 
After Institutional Review Board approval, we retrospectively reviewed the records of all patients with DBDC 
Variable
LRFFS OS
HR (95% CI) p-value HR (95% CI) p-value
Preoperative CEA (≥5 ng/mL) 2.169 (1.111–4.237) 0.023 — —
Resection margin (R1) 3.912 (1.835–8.343) <0.001 — —
Histologic grade (PD) 2.208 (1.125–4.337) 0.021 — —
T stage (T3, AJCC 7th edition) 3.473 (1.788–6.747) <0.001 — —
N stage (N1, AJCC 7th edition) 4.386 (2.278–8.444) <0.001 — —
Locoregional recurrence risk group 3
   vs Group 2 — — 6.927 (2.120–22.632) 0.001
   vs Group 1 — — 8.258 (3.345–20.388) <0.001
Preoperative CA 19–9 (≥37 U/mL) — — 2.183 (0.926–5.144) 0.074
Postoperative CA 19-9 (≥37 U/mL) — — 2.489 (1.199–5.163) 0.014
Lymphovascular invasion (Positive) — — 2.339 (1.247–4.387) 0.008
Table 3. Multivariate analysis of prognostic factors for locoregional failure-free survival and overall survival. 
CEA, carcinoembryonic antigen; PD, poorly differentiated; AJCC, American Joint Committee on Cancer; CA, 
carbohydrate antigen; LRFFS, locoregional failure-free survival; OS, overall survival; HR, hazard ratio; CI, 
confidence interval. Group 1 was defined as patients with positive resection margin or positive lymph nodes. 
Group 2 was defined as patients with negative resection margin and negative lymph nodes who possessed 2 
or more risk factors (preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage). 
Group 3 was defined as patients with negative resection margin and negative lymph nodes with 1 or no risk 
factor (preoperative CEA level ≥ 5 ng/mL, poorly differentiated histologic grade, and T3 stage).
Group Definition
Number of 
Patients
Group1 Patients with R1 resection or positive lymph node 42
Group2 R0 resection and N0 patients who possessed two to three risk factors (preoperative CEA level ≥ 5 [ng/mL], poorly differentiated histologic grade, and T3 stage) 12
Group3 R0 resection and N0 patients who did not exhibit any risk factors or had one risk factor (preoperative CEA level ≥ 5 [ng/mL], poorly differentiated histologic grade, and T3 stage) 39
Table 4. Locoregional recurrence risk groups according to locoregional recurrence risk factors. CEA, 
carcinoembryonic a ntigen.
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adenocarcinoma who underwent curative surgical resection between January 2001 and December 2013. The inclu-
sion criteria were no distant metastasis and an Eastern Cooperative Oncology Group performance status of ≤2. 
Patients were excluded if they received neoadjuvant therapy or adjuvant radiotherapy; patients with ampullary and 
duodenal carcinomas were also excluded from this study. Finally, 93 patients with DBDC, confirmed by pathological 
diagnosis after surgical resection, were included in this study. The primary outcome was the 3-year LRFFS in patients 
undergoing surgical resection for distal bile duct cancer; the secondary outcomes were OS and patterns of failure.
The type of surgery selected was determined according to the location of the tumor: if the tumor was located 
in the distal bile duct, pancreaticoduodenectomy was performed; if the tumor was located in the mid portion of 
the bile duct, segmental resection and hepaticojejunostomy were performed. All patients underwent dissection 
of the LNs in the hepatoduodenal ligament, as well as common hepatic artery and celiac axis LNs. Patients with 
histologically positive LNs or poorly differentiated DBDC considering the histologic grade were usually treated 
with adjuvant chemotherapy. Adjuvant 5-fluorouracil-based or gemcitabine-based chemotherapy was adminis-
tered at the physician’s discretion.
The disease stage for all patients was determined according to the 7th edition of the American Joint Committee on 
Cancer System. Positive margins were defined as the presence of at least 1 cancer cell at the RM on microscopic exam-
ination. CA 19–9 level of 37 U/mL and CEA level of 5 ng/mL was defined as a cutoff value for normal level2,6,8,15–17.
Patients were followed-up 1 month after the operation and every 3 months during the first 12 months, and 
then every 6 months beyond the first year. Patients underwent measurements of CA 19–9 and CEA, and under-
went computed tomography. The postoperative CA 19–9 level was measured between 1 week and 1 month after 
surgical resection. Tumor recurrences were confirmed using radiological imaging techniques and pathological 
studies of histological specimens, with the majority being made by radiological evaluation, including computed 
tomography and positron emission tomography. Recurrence was also confirmed pathologically by biopsy or via 
radiological findings. In this study, only the initial recurrence was evaluated. Locoregional recurrence was defined 
as recurrence in the primary tumor bed and regional lymphatic areas. All other recurrences were considered 
distant metastasis.
Survival was calculated from the date of surgical resection. All events were measured from the date of surgery 
to the date of recurrence. A chi-square test or Fisher exact test was used for comparison of categorical variables 
between groups. Survival was estimated by using the Kaplan–Meier method and compared with the log-rank test. 
Multivariate analysis was performed using a Cox proportional hazards model, and the hazard ratio with a 95% 
confidence interval was determined. We performed a multivariate analysis using backwards elimination to stay in 
the model. A p-value of <0.05 indicated statistical significance.
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